# Regeneron Stock Downgraded to Hold

> Regeneron's stock now priced at $735 near DCF value after rating downgrade.
- Title: Regeneron Stock Downgraded to Hold · Seekingalpha | Shortify
- Summary: Regeneron's stock now priced at $735 near DCF value after rating downgrade. Regeneron Pharmaceuticals stock is downgraded to 'Hold' as its price aligns with…
- Keywords: regeneron, dupixent, eylea, r&d, stock, downgrade, hold, dcf, money, business, Downgraded, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4951833-regeneron-easy-money-made-rating-downgrade
- Author: Stephen Ayers
- Published: 2026-10-04T12:15:05+00:00
- Read time: 1 min
- Topics: regeneron, dupixent, eylea, r&d, stock, downgrade, hold, dcf, money, business
## Rating Downgrade
Regeneron Pharmaceuticals is downgraded to 'Hold' as its stock now appears appropriately priced at $735, near DCF value.
## DUPIXENT Growth
DUPIXENT continues to outperform, driving a 17% revenue jump and providing a strong margin of safety.
## EYLEA HD Durability
EYLEA HD's durability offsets legacy declines, aided by extended dosing intervals and delayed biosimilar competition until 2027.
## R&D Setbacks
R&D setbacks, notably the fianlimab trial failure, weaken the growth thesis; near-term catalysts include Q3 results and the cemdisiran decision.
## Analyst Background
Stephen Ayers has a background as a RN and completed an MBA, analyzing healthcare stocks through clinical data and DCF modeling.
## Key takeaway

Regeneron Pharmaceuticals stock is downgraded to 'Hold' as its price aligns with discounted cash flow valuation.